Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nerveli

Explore full profile

Empathetic pain recovery assistant combining medical science, gamified Cognitive Behavioral Therapy, and machine learning for personalized support

Dallas, United StatesFounded 2022Health
Valuation <$5M Last recorded · 2025
Headcount <100 Current team size
Total funding $0–10M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Nerveli and the history behind them.

About Nerveli

Nerveli is a pioneering company in the field of chronic pain management, offering an empathetic and interactive pain recovery assistant through its mobile app. The app combines proven medical science, gamified Cognitive Behavioral Therapy (CBT), and machine learning algorithms to provide personalized support and recommendations to users. Nerveli primarily serves individuals suffering from chronic pain, aiming to reduce their stress and uncertainty by offering evidence-based and personalized recommendations. The company operates in the healthcare and wellness market, focusing on digital health solutions. Nerveli's business model revolves around offering a subscription-based service, with an initial beta testing program that rewards early adopters with lifetime free access. The company generates revenue through subscription fees and potentially through partnerships with healthcare providers and institutions.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2022
Headquarters
Dallas, United States
Employees
11
Open positions
4
Dealroom signal
86.3/100
Industry
Health
Sector
Health, Psychology, Mental Health, Chronic Disease, Digital Therapeutics, pain care
Business model
SaaS
Client focus
b2b

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Oct 2025 $540K $2.2M 2 the Moon Ventures · DSW Ventures · George Baker Sr. ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Nerveli website traffic

Latest recorded traffic for Nerveli is 1K monthly website visits, up 244.8% over the last three months. Nerveli's team grew 0% over the past year.

Latest monthly visits1K 3-month web change+244.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • DSW Ventures
  • 2 the Moon Ventures
  • George Baker Sr.
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nerveli on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nerveli’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.